Search
Chimeric antigen receptor T-cells
go.drugbank.com/drugs/DB22146InvestigationalChimeric Antigen Receptor T-cells is under investigation in clinical trial NCT05225363 (Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian
Teverelix
go.drugbank.com/drugs/DB05624InvestigationalA synthetic decapeptide, water-soluble Gonadotropin-releasing hormone antagonist. It has reached phase II clinical trials.
Pralnacasan
go.drugbank.com/drugs/DB04875ExperimentalPralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE).
Urelumab
go.drugbank.com/drugs/DB12077InvestigationalUrelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. … The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with
IPH 1101
go.drugbank.com/drugs/DB05754ExperimentalIPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens which specifically activate the Vγ9Vδ2 T cell subset. IPH 1101 is the most advanced drug candidate of the γδ T cell platform
Diethylnorspermine
go.drugbank.com/drugs/DB06445InvestigationalSynonyms: N(1),N(11)-Diethylnorspermine, 1,3-PROPANEDIAMINE, N,N'-BIS(3-(ETHYLAMINO)PROPYL)-